The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus.

Autor: Bando, Yukihiro, Ogawa, Ayumi, Ishikura, Kazuhide, Kanehara, Hideo, Hisada, Azusa, Notumata, Kazuo, Okafuji, Kazuhiro, Toya, Daisyu
Zdroj: Diabetology International; Jun2017, Vol. 8 Issue 2, p218-227, 10p
Abstrakt: We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio ( L/ S ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglobin A1c (HbA1c) levels, 8.1 ± 0.9%; body mass index (BMI), 27.5 ± 3.3 kg/m] were randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; ipragliflozin group; n = 40) or continued treatment (control group; n = 22) for 12 weeks. The primary endpoints were changes in ALT levels; the secondary endpoints included changes in the L/ S ratio and in the visceral fat area (VFA) and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as assessed by computed tomography. ALT levels (−12.45 vs. +5.82 IU/l, P < 0.001), L/ S ratio (+0.07 vs. −0.08, P < 0.001), SFA (−5.8 vs. +13.3 cm, P < 0.05), and VFA (+1.4 vs. +20.4 cm, P < 0.05) significantly changed from baseline in the ipragliflozin group compared with the values in the control group. Multiple regression analysis among all subjects revealed that the independent factor contributing to the %ΔALT and %Δ L/ C ratio was treatment group alone (ipragliflozin group = 1; control group = 0; β coefficient = −32.08, P < 0.001 and β coefficient = 19.98, P < 0.05, respectively). Thus, ipragliflozin may lower ALT levels associated with increased L/ S ratios, indicating its potential therapeutic efficacy in T2DM-associated hepatic steatosis. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: